Lopinavir Monotherapy: High Risk for Viral Relapse in the Central Nervous System

HIV/AIDS Clinical Care: "The trial was stopped prematurely when 6 of the 29 patients on [Kaletra] monotherapy — versus none of the 31 on triple-drug therapy — experienced treatment failure in the blood (defined as 2 consecutive plasma viral loads >400 copies/mL). These failures all occurred within the first 6 months of monotherapy and in patients who had nadir CD4 counts <200 cells/mm3; four of the patients developed neurological symptoms."